Immune checkpoint inhibitors are now at the center of the clinical treatment of metastatic non-small-cell lung cancer (NSCLC). In 2017, the European Commission granted successive approvals to three immune checkpoint inhibitors for bladder cancer: Opdivo, Keytruda, and Tecentriq. In the same year, label expansions were granted to Opdivo for squamous cell carcinoma of the head and neck (SCCHN) and to Tecentriq for NSCLC. As premium-priced immune checkpoint inhibitors enter novel indications and patient populations, payer-imposed reimbursement restrictions and cost-containment strategies will increasingly play a pivotal role in shaping medical oncologists’ prescribing practices and, in turn, determining the commercial success of immune checkpoint inhibitors.
- What are the key driving forces and constraints that influence EU5 payers’ reimbursement decisions for immune checkpoint inhibitors in NSCLC, bladder cancer, and SCCHN?
- How do market access and reimbursement policies at the national, regional, and local level shape prescribing preferences for immune checkpoint inhibitors?
- How do payers prioritize diminishing budgets and control prescribing of immune checkpoint inhibitors?
- How do oncologists view emerging immune checkpoint inhibitors, and do they expect to prescribe them? To what extent will EU5 payer policy likely impact the uptake of these novel agents?
Access & Reimbursement reports provide in-depth insight regarding the impact of payer policies on physician prescribing behavior so that clients can build their market access strategy and optimize their brand positioning.
Actionable recommendations to optimize market access, market access success and stumbles, market access roadblocks, reimbursement dynamics, the impact of pricing and reimbursement, policy, and coverage on prescribing.
Scope of Report:
- Geography: France, Germany, Italy, Spain, and the United Kingdom (i.e., EU5).
- Primary research: Survey of 250 medical oncologists in the EU5 (50 per country) and interviews with 10 EU5 payers (2 per country).
- Key drugs covered: Opdivo, Keytruda, Tecentriq.
- Detailed, Expanded Analysis: Non-Small Cell Lung Cancer, Bladder Cancer and SCCHN (EU)
- Immune Checkpoint Inhibitors - EU5 - Access & Reimbursement
Author(s): Henrique Duarte; Yulia Privolnev, MA
Henrique Duarte is an analyst on the Global Market Access Insights team at Decision Resources Group, primarily focusing on European market access. He is responsible for monitoring, analyzing, and reporting on global market access through the production of DRG’s Global Market Access Solution (GMAS) and Access & Reimbursement products. Henrique’s specific focus is on all aspects of market access in the EU5, as well as in select Latin American countries. Henrique holds a pharmaceutical science degree from the Universidade Lusófona and a postgraduate certificate in health economics from the University of York.
Yulia Privolnev is a manager on the Global Market Access Insights team at Decision Resources Group, primarily focusing on European market access. She is responsible for monitoring, analyzing, and reporting on global market access through the production of DRG’s Global Market Access Solution (GMAS) and Access & Reimbursement products. Yulia’s specific focus is on all aspects of market access in Western and Eastern Europe, as well as external reference pricing (ERP) and managed entry agreements (MEAs) on a global scale. Yulia holds a bachelor’s degree from the University of Toronto and a master’s degree from the London School of Economics.